Perspectives on Treating CCA Moving Forward
A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.
Immunotherapy for Advanced Cholangiocarcinoma
The role of MSI testing and potential use of immunotherapy to treat patients with advanced cholangiocarcinoma.
Cholangiocarcinoma: Potential Therapies Under Investigation
An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.
IDH Targeting in Advanced Cholangiocarcinoma
Considerations for treating appropriate patients with advanced cholangiocarcinoma with an IDH inhibitor.
Implications for Using FGFR Inhibitors in Advanced CCA
Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.
FGFR Inhibitors for Advanced Cholangiocarcinoma: Adverse Events
Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.
FGFR Inhibitors for Advanced Cholangiocarcinoma
R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.
Promoting the Importance of Molecular Testing in CCA
The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.
Open Questions and Future Directions in mCRC
Experts in CRC discuss questions and management of mCRC.
Using Molecular Testing to Guide Treatment Selection in mCRC
John Marshall, MD, and Axel Grothey, MD, discuss how molecular testing results guide treatment decisions in patients with mCRC.
TAS-102 in Third or Fourth Line for mCRC
Experts in mCRC review data on TAS-102 and discuss how best to sequence therapies in the third or fourth line.
Regorafenib in Third or Fourth Line for mCRC: Safety in the Re-DOS Trial
Axel Grothey, MD, and John Marshall, MD, discuss safety results from the ReDOS study of regorafenib in patients with mCRC.
Regorafenib in Third or Fourth Line for mCRC: Efficacy in the Re-DOS Trial
John Marshall, MD, reviews efficacy data from the ReDOS study of regorafenib in patients with mCRC.
Therapy After Progression in mCRC
Experts in metastatic colorectal cancer review therapeutic options after progression for patients with mCRC.
Maintenance or Chemo-Free Interval in mCRC
Experts in metastatic colorectal cancer discuss when and in which patients to use a chemotherapy-free treatment interval.
Optimizing First-Line Therapy in mCRC
Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.
First-Line Options in mCRC
Axel Grothey, MD, and John Marshall, MD, discuss first-line treatment options in patients with metastatic colorectal cancer.
Treatment Considerations in mCRC
Axel Grothey, MD, discusses factors that influence treatment selection in patients with mCRC.
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
2 Commerce Drive Cranbury, NJ 08512